Acalabrutinib and Obinutuzumab for Frontline CLL Treatment

(8:31)

How CALQUENCE® (acalabrutinib) Works

(2:18)

CALQUENCE® (acalabrutinib) Perspectives: Dr Alexey Danilov, MD, PhD

(12:20)

Acalabrutinib And Zanubrutinib in CLL

(19:32)

CALQUENCE® (acalabrutinib) Safety Data – Dr Levy, MD

(14:9)

Dr. Wang on the Toxicity of Ibrutinib, Acalabrutinib, and Zanubrutinib in MCL

(1:10)

Acalabrutinib Versus Ibrutinib for CLL

(5:44)

Dr. Abedin Discusses Differences Between Acalabrutinib and Ibrutinib in CLL

(1:25)

Acalabrutinib May Be an Alternative to Ibrutinib For Treatment of CLL

(1:37)

CALQUENCE® (acalabrutinib) Patient Testimonials: Jim’s Story

(4:11)

Which CLL Treatment Is Right for You? What You Need to Know

(29:38)

CALQUENCE® (acalabrutinib) ACE-CL-001 (ibrutinib-intolerant cohort) – Dr Raval, MD

(18:35)

Lung Cancer Warning Signs II Lung Cancer Symptoms

(3:54)

Update on BTK inhibitors for CLL: Ibrutinib pus the new kids on the block: Are they better?

(21:42)

CLL treatment New Options, More Hope

(1:8:25)

New frontiers and emerging treatments for CLL

(1:3:50)

CALQUENCE® (acalabrutinib) Patient Management \u0026 Adherence – Bradley, NP

(16:42)

CALQUENCE® (acalabrutinib) Patient Testimonials :Doreen’s Story

(10:34)

The current role of acalabrutinib in the treatment of CLL

(1:15)

Selecting between ibrutinib, acalabrutinib and zanubrutinib in the frontline setting in CLL

(2:57)

Acalabrutinib in patients with CLL and MCL undergoing alloSCT

(55)

CALQUENCE® (acalabrutinib) Mechanism of Action (MOA) – Dr Pearson, MD

(12:16)

CALQUENCE® (acalabrutinib) Perspectives: Dr Tara Graff, DO

(11:27)

CALQUENCE® (acalabrutinib) ELEVATE-TN, Including 6-Year Median Follow-Up Data – Dr O’ Brien, MD

(22:4)

Dr. Woyach on 3-Year Follow-Up of Acalabrutinib/Obinutuzumab Combo in CLL

(1:20)

Acalabrutinib for Treating Mantle Cell Lymphoma

(3:46)

CALQUENCE® (acalabrutinib) MAIC of ASCEND and ALPINE – Dr Skarbnik, MD

(20:1econd)

CALQUENCE® (acalabrutinib) ELEVATE-RR and ASCEND Data – Dr Ma, MD

(19:)

Acalabrutinib, Second-Generation BTK Inhibitor for CLL

(8:38)